Ibio, Inc. last reported quarterly results on Aug 28, 2026, for Q4 FY2026 (the quarter ended Jun 30, 2026): revenue of $0 (-100.0% year over year) and diluted EPS of -$0.07. It usually reports 41–59 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 11, 2026.
Results for Q1 FY2027, the quarter ending around Sep 30, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Nov 12, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 41–59 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 28, 2026
59 days after quarter end
|
Q4 FY2026
ended Jun 30, 2026
|
0
-100.0%
|
-11
-105.3%
|
-0.07
+79.7%
|
|
May 12, 2026
42 days after quarter end
|
Q3 FY2026
ended Mar 31, 2026
|
0
|
-8
-59.0%
|
-0.06
+87.8%
|
|
Feb 10, 2026
41 days after quarter end
|
Q2 FY2026
ended Dec 31, 2025
|
0
-100.0%
|
-9
-106.1%
|
-0.09
+81.3%
|
|
Nov 12, 2025
43 days after quarter end
|
Q1 FY2026
ended Sep 30, 2025
|
0
|
-6
-43.4%
|
-0.11
+76.1%
|
|
Aug 18, 2025
49 days after quarter end
|
Q4 FY2025
ended Jun 30, 2025
|
0
+14.3%
|
-5
|
-0.36
|
|
May 2, 2025
32 days after quarter end
|
Q3 FY2025
ended Mar 31, 2025
|
0
|
-5
|
-0.49
+42.4%
|
|
Feb 10, 2025
41 days after quarter end
|
Q2 FY2025
ended Dec 31, 2024
|
0
|
-4
|
-0.48
+89.1%
|
|
Nov 12, 2024
43 days after quarter end
|
Q1 FY2025
ended Sep 30, 2024
|
0
-100.0%
|
-4
|
-0.46
+90.4%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IBIO (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1420720
- Former names
- iBio, Inc. (until Oct 19, 2026); iBioPharma, Inc. (until Aug 14, 2009); InB:Biotechnologies, Inc. (until Jul 17, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.